Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd.QNRX · Entity 7876 | Director | February 04, 2026 | February 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Quoin Pharmaceuticals Ltd.
Report date February 04, 2026 · Filed February 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.37 · Expires 2036-02-04 | Direct | 8,141 |
Reported balance
After 2026-02-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-04 · Grant · Acquired 8,141 · Balance 8,141 F1: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. F2: The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030. |
Filing footnotes · ownership attribution and instrument terms
F1: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.
F2: The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 04, 2026 Filed Feb 6, 2026 17:14 UTC | Quoin Pharmaceuticals Ltd. QNRX · Entity 7876 | GrantShare Option (Right to Buy) · Derivative | 8,141 | $0.00 Strike: $7.37 | $0.00 |
DisclosureSEC source: 0001104659-26-011610 · tm265448-2_4seq1.xml · derivative · entry 1 SEMBER MICHAEL T · CIK 0001107486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,141 Underlying: ADS · 8,141 shares Expires 2036-02-04 F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. F1 · shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. F2 · derivative.exercise_date: The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030. F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. F1 · balance_after: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:36 UTC | Quoin Pharmaceuticals Ltd. QNRX · Entity 7876 | GrantShare Option (Right to Buy) · Derivative | 7,760 | $0.00 Strike: $9.07 | $0.00 |
DisclosureSEC source: 0001104659-25-055626 · tm2516320-1_4seq1.xml · derivative · entry 1 SEMBER MICHAEL T · CIK 0001107486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,760 Underlying: ADS · 7,760 shares Expires 2035-05-29 F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. F1 · shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. F2 · derivative.exercise_date: The option vests in four annual installments with 20% vesting on each of May 29, 2026, 2027 and 2028 and 40% vesting on May 29, 2029. F1 · derivative.underlying: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. F1 · balance_after: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 16:47 UTC | Quoin Pharmaceuticals Ltd. QNRX · Entity 7876 | GrantShare Option (Right to Buy) · Derivative | 50,714 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001104659-24-127238 · tm2430519-4_4seq1.xml · derivative · entry 1 SEMBER MICHAEL T · CIK 0001107486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,714 Underlying: ADS · 50,714 shares Expires 2034-12-09 F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer. F1 · shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer. F2 · derivative.exercise_date: The option vests in four annual installments with 20% vesting on each of December 9, 2025, 2026 and 2027 and 40% vesting on December 9, 2028. F1 · derivative.underlying: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer. F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer. F1 · balance_after: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer. Read SEC document |
| October 26, 2023 Filed Oct 30, 2023 16:14 UTC | Quoin Pharmaceuticals Ltd. QNRX · Entity 7876 | GrantShare Option (Right to Buy) · Derivative | 7,652 | $0.00 Strike: $5.75 | $0.00 |
DisclosureSEC source: 0001104659-23-112572 · tm2329341-8_4seq1.xml · derivative · entry 1 SEMBER MICHAEL T · CIK 0001107486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,652 Underlying: American Depositary Share · 7,652 shares Expires 2033-10-26 F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"), with sixty thousand (60,000) ordinary shares of the Issuer represented by one (1) ADS. F1 · shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"), with sixty thousand (60,000) ordinary shares of the Issuer represented by one (1) ADS. F2 · derivative.exercise_date: The option vests in four annual installments with 20% vesting on each of October 26, 2024, 2025 and 2026 and 40% vesting on October 26, 2027. F1 · derivative.underlying: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"), with sixty thousand (60,000) ordinary shares of the Issuer represented by one (1) ADS. F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"), with sixty thousand (60,000) ordinary shares of the Issuer represented by one (1) ADS. F1 · balance_after: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"), with sixty thousand (60,000) ordinary shares of the Issuer represented by one (1) ADS. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.